(Reuters) - Sarepta Therapeutics Inc said patients trialing its muscle wasting disorder drug showed an accelerated decline in walking ability after nearly three years of use, sending the company's shares down as much as 28 percent.
via Reuters: Health News Read More Here..
No comments:
Post a Comment